Search Results - "NORDEN, A. D"

Bevacizumab for recurrent malignant gliomas : Efficacy, toxicity, and patterns of recurrence by NORDEN, A. D, YOUNG, G. S, KESARI, S, WEN, P. Y, SETAYESH, K, MUZIKANSKY, A, KLUFAS, R, ROSS, G. L, CIAMPA, A. S, EBBELING, L. G, LEVY, B, DRAPPATZ, J

“…Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some…”
Get full text

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure by Lu-Emerson, C., Norden, A. D., Drappatz, J., Quant, E. C., Beroukhim, R., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Ruland, S., Wen, P. Y.

“…There is no effective treatment for recurrent glioblastoma (GBM) after bevacizumab failure. Putative mechanisms of resistance to bevacizumab include increased…”
Get full text

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma by Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., Gerard, M., Schiff, D., Chi, A. S., Batchelor, T. T., Doherty, L. M., Ciampa, A. S., LaFrankie, D. C., Ruland, S., Snodgrass, S. M., Raizer, J. J., Wen, P. Y.

“…Bevacizumab is frequently used to treat patients with recurrent high-grade glioma (HGG), but responses are generally not durable. Panobinostat is a histone…”
Get full text

Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board by Somashekhar, S.P., Sepúlveda, M.-J., Puglielli, S., Norden, A.D., Shortliffe, E.H., Rohit Kumar, C., Rauthan, A., Arun Kumar, N., Patil, P., Rhee, K., Ramya, Y.

“…Breast cancer oncologists are challenged to personalize care with rapidly changing scientific evidence, drug approvals, and treatment guidelines. Artificial…”
Get full text

Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma by Van Meir, Erwin G., Hadjipanayis, Costas G., Norden, Andrew D., Shu, Hui‐Kuo, Wen, Patrick Y., Olson, Jeffrey J.

“…Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although…”
Get full text

Medical management of brain tumors and the sequelae of treatment by Schiff, David, Lee, Eudocia Q, Nayak, Lakshmi, Norden, Andrew D, Reardon, David A, Wen, Patrick Y

“…Patients with malignant brain tumors are prone to complications that negatively impact their quality of life and sometimes their overall survival as well…”
Get full text

Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C) by Gutierrez, M.E., Norden, A.D., Lane, D.C., Canavan, B.F., Nwokeji, E.D., Xu, Y., Kaur, S., Goldberg, S.L., Noh, L., Siegartel, L., Whittington, J., Tuell, K., Korytowsky, B.

Get full text

Are treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions? by Atieh Graham, D.M., McNamara, D.M., Waintraub, S.E., Goldberg, S.L., Norden, A.D., Hervey, J., Pecora, A.L., Landstrom, C., Snowdon, J.L., Francis, P.M., Jungbluth, N., Wang, C.K., Latts, L.

Get full text

Positive and Negative Network Correlations in Temporal Lobe Epilepsy by Blumenfeld, Hal, McNally, Kelly A., Vanderhill, Susan D., Paige, A. LeBron, Chung, Richard, Davis, Kathryn, Norden, Andrew D., Stokking, Rik, Studholme, Colin, Novotny, Edward J., Zubal, I. George, Spencer, Susan S.

“…Temporal lobe seizures are accompanied by complex behavioral phenomena including loss of consciousness, dystonic movements and neuroendocrine changes. These…”
Get full text

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues by Dietrich, Jörg, Norden, Andrew D, Wen, Patrick Y

“…To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of…”
Get full text

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma by Lee, Eudocia Q, Reardon, David A, Schiff, David, Drappatz, Jan, Muzikansky, Alona, Grimm, Sean A, Norden, Andrew D, Nayak, Lakshmi, Beroukhim, Rameen, Rinne, Mikael L, Chi, Andrew S, Batchelor, Tracy T, Hempfling, Kelly, McCluskey, Christine, Smith, Katrina H, Gaffey, Sarah C, Wrigley, Brendan, Ligon, Keith L, Raizer, Jeffrey J, Wen, Patrick Y

“…Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We…”
Get full text

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 by Wen, Patrick Y, Chang, Susan M, Lamborn, Kathleen R, Kuhn, John G, Norden, Andrew D, Cloughesy, Timothy F, Robins, H Ian, Lieberman, Frank S, Gilbert, Mark R, Mehta, Minesh P, Drappatz, Jan, Groves, Morris D, Santagata, Sandro, Ligon, Azra H, Yung, W K Alfred, Wright, John J, Dancey, Janet, Aldape, Kenneth D, Prados, Michael D, Ligon, Keith L

“…Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade…”
Get full text

1589PAre treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions? by Atieh Graham, D M, McNamara, D M, Waintraub, S E, Goldberg, S L, Norden, A D, Hervey, J, Pecora, A L, Landstrom, C, Snowdon, J L, Francis, P M, Jungbluth, N, Wang, C K, Latts, L

Get full text

1229PReal world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C) by Gutierrez, M E, Norden, A D, Lane, D C, Canavan, B F, Nwokeji, E D, Xu, Y, Kaur, S, Goldberg, S L, Noh, L, Siegartel, L, Whittington, J, Tuell, K, Korytowsky, B

Get full text

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma by Norden, Andrew D, Lesser, Glenn J, Drappatz, Jan, Ligon, Keith L, Hammond, Samantha N, Lee, Eudocia Q, Reardon, David R, Fadul, Camilo E, Plotkin, Scott R, Batchelor, Tracy T, Zhu, Jay-Jiguang, Beroukhim, Rameen, Muzikansky, Alona, Doherty, Lisa, Lafrankie, Debra, Smith, Katrina, Tafoya, Vida, Lis, Rosina, Stack, Edward C, Rosenfeld, Myrna R, Wen, Patrick Y

“…Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown. Resistance to temozolomide is partially mediated…”
Get full text

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab by Rahman, Rifaquat, Hempfling, Kelly, Norden, Andrew D, Reardon, David A, Nayak, Lakshmi, Rinne, Mikael L, Beroukhim, Rameen, Doherty, Lisa, Ruland, Sandra, Rai, Arun, Rifenburg, Jennifer, LaFrankie, Debra, Alexander, Brian M, Huang, Raymond Y, Wen, Patrick Y, Lee, Eudocia Q

“…Currently, there are no known effective treatments for recurrent glioblastoma once patients have progressed on a bevacizumab-containing regimen. We examined…”
Get full text

Essential fatty acid deficiency in patients with lesions of the gastrointestinal tract by Wapnick, Simon, Norden, Daphne A., Venturas, Dawn J.

“…The relative amounts of unsaturated fatty acids in the serum lipids of 14 patients who have undergone small bowel resection have been investigated. These…”
Get full text

A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma by Nghiemphu, P. L., Omuro, A. M., Cloughesy, T., Mellinghoff, I. K., Norden, A. D., Nguyen, L. T., Rajangam, K., Wen, P. Y.

“…Abstract only…”
Get full text

Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients by Bartolomeo, J., Norden, A. D., Drappatz, J., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Quant, E. C., Beroukhim, R., Wen, P. Y.

“…Abstract only…”
Get full text

Retrospective study of dasatinib in recurrent high-grade glioma (HGG) patients who failed bevacizumab by Lu-Emerson, C., Norden, A. D., Drappatz, J., Quant, E. C., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Wen, P. Y.

“…Abstract only…”
Get full text